RNA vaccines are hugely versatile. They can potentially inoculate against any pathogen for which a protein target is known, for example, influenza, chlamydia, HIV-1 (human immunodeficiency virus 1), Ebola and RSV (respiratory syncytial virus). Self-amplifying RNA (saRNA) is a typ...
Lipid Nanoparticles (LNPs) are nanoparticles formed by lipid components that are one of the effective means for mRNA delivery. Although the emergence of variants of COVID-19 has encouraged greater demands for developing mRNA–LNP vaccines, its benefits extend beyond vaccinations t...
Limit size behavior, in-line dilution and tangential flow filtration are important process considerations to evaluate and optimize during process development.
Nanomedicine offers promising therapeutic solutions for cell and gene therapies, autoimmune diseases, oncology, rare inherited diseases and more. Some new avenues to explore include early disease detection or molecularly tailored treatments for patients who have complex diseases ...
The production of RNA lipid nanoparticles (LNPs) such as those used in COVID-19 vaccines involves mixing RNA in an aqueous buffer with lipids dissolved in ethanol to trigger the self-assembly of LNPs. The mixing conditions of the RNA and lipids are crucial to drug product quality...
COVID vaccine development has proven that genomic medicines have the potential for faster drug development. Along with potential therapies across screening, prevention, and treatment options, genomic medicines can target the disease-causing gene mutations, offering a more accurat...
Scale-up and downstream processing operations can impact the functionality and stability of mRNA-LNPs in vaccine development including COVID-19 vaccines.
Sign up today to automatically receive new Precision NanoSystems application notes, conference posters, relevant science publications, and webinar invites.